Brodalumab success in patients with moderate-to-severe psoriasis who failed previous interleukin-17A inhibitors

Jensen Yeung; Ron Vender; Irina Turchin; Rahul Shukla; Catherine Maari; Chih-Ho Hong; Maxime Barakat; Perla Lansang

doi:10.1016/j.jaad.2020.11.013

Brodalumab success in patients with moderate-to-severe psoriasis who failed previous interleukin-17A inhibitors

J Am Acad Dermatol. 2021 Apr;84(4):1169-1171. doi: 10.1016/j.jaad.2020.11.013. Epub 2020 Nov 19.

Authors

Jensen Yeung¹, Ron Vender², Irina Turchin³, Rahul Shukla⁴, Catherine Maari⁵, Chih-Ho Hong⁶, Maxime Barakat⁷, Perla Lansang⁸

Affiliations

¹ Department of Dermatology, Women's College Hospital, Toronto, Ontario, Canada; Division of Dermatology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada; Division of Dermatology, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; Probity Medical Research, Waterloo, Ontario, Canada. Electronic address: jensen.yeung@utoronto.ca.
² Department of Medicine, Division of Dermatology, McMaster University, Hamilton, Ontario, Canada; Dermatrials Research Inc, Hamilton, Ontario, Canada.
³ Brunswick Dermatology Center, Fredericton, New Brunswick, Canada; Dalhousie University, Halifax, Nova Scotia, Canada; Probity Medical Research, Waterloo, Ontario, Canada.
⁴ Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.
⁵ Division of Dermatology, Faculty of Medicine, Montreal University Hospital Center, Montreal, Quebec, Canada.
⁶ Department of Dermatology and Skin Science, University of British Columbia, Vancouver, British Columbia, Canada; Probity Medical Research, Waterloo, Ontario, Canada.
⁷ Bausch Health Companies, Laval, Quebec, Canada.
⁸ Department of Dermatology, Women's College Hospital, Toronto, Ontario, Canada; Division of Dermatology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada; Division of Dermatology, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; The Hospital for Sick Children, Toronto, Ontario, Canada.

PMID: 33221464
DOI: 10.1016/j.jaad.2020.11.013

No abstract available

Publication types

Multicenter Study

MeSH terms

Adult
Antibodies, Monoclonal, Humanized / therapeutic use*
Dermatologic Agents / therapeutic use*
Female
Humans
Interleukin-17 / antagonists & inhibitors
Male
Middle Aged
Psoriasis / drug therapy*
Retrospective Studies
Severity of Illness Index
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Dermatologic Agents
Interleukin-17
brodalumab